Proof of Concept Study of Vagus Nerve Stimulation

Status Completed

Clinical Trial Summary

The investigator's recent pilot study of vagus nerve stimulation (VNS) from a surgically implanted medical device to control the excess eating behaviour characteristic of Prader-Willi Syndrome (PWS) found that it was safe and acceptable. In addition, there were unanticipated marked improvements in rates of problem behaviours, such as emotional disturbances and verbal and physical outbursts. These observations indicated the need for a trial specifically focusing on the effects of VNS on problem behaviour and also that the use of VNS might be extended to include people with other neurodevelopmental disorders, such as autism spectrum conditions (ASC). The primary aims of this study are: a) to investigate whether VNS, now given by an external medical device, is associated with a significant reduction in the number and severity of maladaptive behaviours in adults with PWS; and b) to undertake a pilot study that includes others with a different neurodevelopmental syndrome who have histories of similar behaviours.

The study will be a single case cross-over design with 4 to 6 months baseline phase and a similar period of active treatment. The study cannot be blind as the stimulation is apparent but the participants will wear the device initially for four hours a day, at times convenient to them, with it switched off in the baseline phase and activated, according to standard protocols, in the treatment phase. Six adults with PWS and six with a different neurodevelopmental disorder with histories of significant problem behaviours will be included initially, with a view to extending if the analysis indicates a likely effect. Behaviours will be operationally defined and measured over time using participant and informant diaries with additional secondary outcome measures. Before and during the treatment phases autonomic nervous system and brain biomarkers will be assessed using ambulatory monitoring of heart rate variability and fMRI brain scans.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Neurodevelopmental Disorders
Prader-Willi Syndrome
Syndrome
Transcutaneous Vagal Nerve Stimulation (tVNS)

Clinical Trial Details

NCT number	NCT03689621
Study type	Interventional
Source	University of Cambridge
Contact
Status	Completed
Phase	N/A
Start date	January 1, 2016
Completion date	December 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05032326` - Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial	Phase 3
Completed	`NCT04526379` - Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation	N/A
Terminated	`NCT03458416` - A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome	Phase 2
Completed	`NCT03718416` - Natural History Study of Serious Medical Events in PWS
Completed	`NCT05322096` - Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome	Phase 2
Completed	`NCT02205450` - Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
Terminated	`NCT02179151` - Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome	Phase 3
Completed	`NCT00375089` - Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity	N/A
Completed	`NCT00004351` - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes	N/A
Recruiting	`NCT05938543` - Cerebellar TMS and Satiety in Prader-Willi Syndrome	N/A
Suspended	`NCT05879614` - An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)	Phase 2
Recruiting	`NCT03031626` - Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome	Phase 4
Withdrawn	`NCT04086810` - An Open-Label Study of DCCR Tablet in Patients With PWS	Phase 3
Completed	`NCT02629991` - Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome	Phase 2
Recruiting	`NCT02297022` - Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome	Phase 1
Not yet recruiting	`NCT02263781` - PREPL in Health and Disease	N/A
Completed	`NCT00551343` - Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome	N/A
Recruiting	`NCT06448871` - Ultrasound to Assess Sarcopenia in Prader Willi Syndrome
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Recruiting	`NCT05939453` - Impact of Bright Light Therapy on Prader-Willi Syndrome	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.